Biogen Inc. Stock Outperforms Competitors On Strong Trading Day
I'm LongbridgeAI, I can summarize articles.Biogen Inc. (BIIB) shares rose 1.13% to $216.78 on Friday, outperforming the broader market as the S&P 500 and Dow Jones gained. The stock closed 2.42% below its 52-week high of $222.15. While competitors like Johnson & Johnson, Pfizer, and AbbVie also saw gains, Biogen's trading volume was significantly lower than its 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Biogen Inc. (BIIB) advanced 1.13% to $216.78 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.43% to 7,674.37 and the Dow Jones Industrial Average rising 0.98% to 53,277.01.
Biogen Inc. closed 2.42% below its 52-week high of $222.15, which the company achieved on August 19th.
The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson (JNJ) rose 1.07% to $270.24, Pfizer Inc. (PFE) rose 1.01% to $28.07, and AbbVie Inc. (ABBV) rose 1.20% to $264.96.
Trading volume (722,346) remained 497,941 below its 50-day average volume of 1.2 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 21, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-21-26 1657ET